the role of ibrutinib in dlbcl and the value of next-generation btk inhibitors
Published 2 years ago • 155 plays • Length 2:42Download video MP4
Download video MP3
Similar videos
-
1:27
managing cardiotoxicity associated with the use of ibrutinib
-
0:52
rilzabrutinib: a novel promising btk inhibitor being explored in itp
-
1:21
overview of the role of non-covalent btk inhibitors in the era of covalent btk inhibitors
-
2:02
phase ib/iia study of azd4573 and acalabrutinib in patients with r/r dlbcl
-
1:05
final analysis of the alpine trial: zanubrutinib vs ibrutinib in r/r cll
-
3:58
phase ib/iia study of azd4573 acalabrutinib in r/r dlbcl
-
2:20
the effect of ibrutinib dose-reduction on outcomes of patients with cll/sll: real-world evidence
-
2:07
efficacy of ibrutinib in the treatment of cll patients with del(17p) and tp53 mutation
-
3:09
bleximenib combined with venetoclax and azacitidine in r/r aml with kmt2a or npm1 alterations
-
4:01
how amezcua bio light 3 can help heal your body - dr beverly rubik
-
5:59
6-year results of cll14: venetoclax-obinutuzumab for previously untreated cll
-
1:09
ibrutinib added to autosct conditioning and consolidation for patients with abc-dlbcl
-
3:46
the characteristics and mode of action of ibrutinib for cll
-
2:58
results of a phase ib study of ibrutinib obinutuzumab in r/r cll
-
1:12
exciting advances in dlbcl: molecular characterization of subtypes & novel immunotherapeutic agents
-
2:29
real-world comparison of ttnt with ibrutinib or acalabrutinib in cll
-
1:32
genomic evolution & resistance to pirtobrutinib in covalent btk inhibitor pre-treated cll
-
6:05
real-world data on the effect of ibrutinib flexible dosing treatment strategies on ttnt in cll/sll
-
2:56
upcoming trials for dlbcl: r-chop with acalabrutinib and obinutuzumab with checkpoint inhibitor
-
1:51
the use of btk inhibitors in r/r and treatment-naïve patients with wm
-
1:21
ibrutinib, rituximab and venetoclax in the treatment of patients with newly diagnosed mcl
-
1:32
novel btki strategies in indolent b-cell malignancies: pirtobrutinib for fl and mzl